View Archive

Credit Designation

Physicians' Education Resource® (PER®), LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Oncology Best Practice™ Identifying and Treating Patients with TGCT: Best Practices for the Multidisciplinary Team

Oncology Best Practice™ Identifying and Treating Patients with TGCT: Best Practices for the Multidisciplinary Team

Oncology Best Practice™:
Identifying and Treating Patients with TGCT: Best Practices for the Multidisciplinary Team

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668

Dates of Certification
June 2019, to November 2020


This 1.0 AMA credit program will review the pathobiology, current treatment options, and evolving treatment options in tenosynovial giant cell tumors (TGCT). Challenges regarding the recognition and delayed diagnosis of this disease will be discussed with clinicians to improve the recognition of this rare oncologic condition. Experts will place current treatment paradigms in the context of new developments, especially as related to the colony-stimulating factor 1 receptor (CSF1R) inhibitors, which are currently in late-stage clinical development. In addition, this program will inform best practices in multidisciplinary management and care coordination to reduce diagnostic delays and optimize outcomes for patients with TGCT.

Benefits of Attending

  • Gain expert insights into current best practices for the recognition and diagnosis of tenosynovial giant cell tumors (TGCTs)
  • Recognize current treatment options in the context of guidelines and expert-recommended best practices
  • Evaluate the latest safety and efficacy data from clinical trials in TGCT informing current options for clinical trial enrollment and therapies in late-stage development
  • Understand best practices for multidisciplinary care of TCGT to optimize and expedite diagnosis

Target Audience

This educational program is primarily directed toward orthopedic surgeons, sarcoma specialists, and oncologic surgeons who treat and/or diagnose patients with TGCT. Additionally, medical oncologists, fellows, nurses, nurse practitioners, physician assistants, and other healthcare professions (HCPs) involved in the treatment and diagnosis of TGCT will also be invited to participate in the activity.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain challenges associated with the differential diagnosis of TGCT and methods to facilitate its earlier diagnosis
  2. Evaluate recent clinical trial efficacy and safety data of novel pharmacologic therapies for TGCT
  3. Develop evidence-based treatment plans for the various forms of TGCT
  4. Describe the role of multidisciplinary management as a best practice to optimize diagnosis and outcomes for patients with TGCT


William D. Tap
William D. Tap, MD
Medical Oncologist
Chief of Sarcoma
Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Calendar of Events
Filter By